10-QPeriod: Q1 FY2009

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 2009

Filed May 8, 2009For Securities:ALNY

Summary

This 10-Q filing for Alnylam Pharmaceuticals, Inc. (ALNY) as of and for the quarterly period ended March 31, 2009, provides an update on the company's financial position and operational performance. As an early-stage biotechnology company, Alnylam's financial results reflect ongoing investments in research and development, with significant operating losses typical for its business model. Investors should focus on the company's cash burn rate, progress in its pipeline, and its ability to secure future funding or partnerships. The Condensed Consolidated Balance Sheets as of March 31, 2009, and December 31, 2008, will show the company's asset and liability structure, with particular attention to cash and cash equivalents, which are critical for funding operations. The Statements of Operations and Comprehensive Loss for the three months ended March 31, 2009 and 2008, will detail revenue (likely minimal at this stage) and the substantial research and development expenses driving the reported net losses. The Statements of Cash Flows will be crucial for understanding the sources and uses of cash, highlighting the operational cash outflow.

Key Highlights

  • 1The filing presents unaudited financial statements for the three months ended March 31, 2009, offering a snapshot of the company's recent performance.
  • 2Key financial statements include the Condensed Consolidated Balance Sheets, Statements of Operations and Comprehensive Loss, and Statements of Cash Flows.
  • 3Investors should closely examine the company's cash and cash equivalents position as reported on the balance sheet, given the typical high cash burn of biotechnology firms.
  • 4The Statements of Operations will reveal the extent of operating losses, driven primarily by research and development expenditures, which is characteristic of Alnylam's stage of development.
  • 5The Management's Discussion and Analysis (MD&A) section is critical for understanding the company's financial condition, liquidity, and the factors influencing its results of operations.
  • 6Risk Factors are detailed in Part II, providing insight into potential challenges and uncertainties that could impact the company's future performance.
  • 7Progress in Alnylam's pipeline programs, although not explicitly detailed in the financial statement summaries, is the underlying driver of the company's R&D investment and future value.

Frequently Asked Questions

The Condensed Consolidated Balance Sheets as of March 31, 2009, will provide the exact cash and cash equivalents. Investors should analyze this figure in conjunction with the cash flow statement to understand the quarterly cash burn rate and estimate the company's runway for future operations.

The Condensed Consolidated Statements of Operations will show the net loss. This loss is typically driven by significant investments in research and development (R&D) for pipeline drug candidates, which is a common characteristic of early-stage biotechnology companies. The MD&A section will offer more context on the specific R&D activities.

Part II, Item 1A, lists the Risk Factors. Investors should review this section for any updates or newly identified risks related to Alnylam's clinical trials, regulatory approvals, intellectual property, competition, or financing needs.

As an early-stage biotechnology company, Alnylam likely had minimal to no product revenue. Revenue, if any, might be derived from collaboration agreements or licensing. The Statements of Operations will clarify the revenue generated during the period.